Can Trazodone and Hydroxyzine Worsen Insomnia?
Yes, both trazodone and hydroxyzine can paradoxically worsen insomnia in some patients, and current evidence suggests neither should be first-line therapy for chronic insomnia disorder. When insomnia worsens on these medications, discontinue them and transition to evidence-based treatments.
The Evidence Against These Medications
Trazodone's Limited Efficacy and Risks
The 2020 VA/DoD guidelines explicitly advise against using trazodone for chronic insomnia disorder 1. Despite being the second most commonly prescribed sleep medication, systematic reviews show trazodone demonstrates no significant improvement in sleep efficiency or objective sleep measures compared to placebo 1. While patients may report subjectively better sleep quality, this improvement is outweighed by its adverse effect profile 1.
The FDA drug label warns of multiple mechanisms by which trazodone can worsen sleep 2:
- Activation/agitation leading to paradoxical insomnia
- Mania or hypomania causing decreased need for sleep and increased energy
- Withdrawal symptoms including anxiety, agitation, and sleep problems when discontinuing
- Orthostatic hypotension causing nighttime awakenings
- Serotonin syndrome with agitation and coordination problems
Recent meta-analyses confirm trazodone extends objective total sleep time by only 28 minutes but does not affect perceived sleep duration 3. Importantly, tolerance develops after 3-4 days of continuous use 1, explaining why initial benefit may disappear or reverse.
Hydroxyzine's Fundamental Problems
Antihistamines like hydroxyzine are explicitly not recommended for chronic insomnia 4. The 2008 AASM guidelines state there is "relative lack of efficacy and safety data" for OTC antihistamines 4. The 2020 VA/DoD guidelines go further, advising strongly against antihistamines due to 1:
- Rapid tolerance development - sedative effects disappear after 3-4 days of continuous use 1
- Antimuscarinic adverse effects - the 2019 Beers Criteria carry a strong recommendation to avoid these drugs in older adults 1
- Paradoxical CNS stimulation - can cause agitation and worsened insomnia, particularly in elderly patients 5
- QT prolongation risk - can cause cardiac arrhythmias and sleep disruption 5
The FDA label explicitly warns that hydroxyzine may cause "confusion and over sedation in the elderly" and that "sedating drugs may cause confusion" 5, both of which can manifest as worsened sleep architecture.
Why Insomnia Worsens: Specific Mechanisms
Common Pathways for Both Medications
Tolerance and Rebound: Both medications lose efficacy within days, leading to rebound insomnia that is worse than baseline 1
Sleep Architecture Disruption: While causing sedation, they may fragment sleep and reduce restorative sleep stages without improving total sleep time perception 3, 6
Paradoxical Activation: Both can cause CNS stimulation in susceptible individuals, particularly elderly patients 1, 5
Withdrawal Effects: Discontinuation causes anxiety, agitation, and severe sleep disruption 2
Appropriate Management Algorithm
Step 1: Immediate Assessment
When insomnia worsens on trazodone or hydroxyzine, evaluate for:
- Timing of worsening - If within first week, likely paradoxical reaction; if after 1-2 weeks, likely tolerance
- New symptoms - Agitation, confusion, daytime sedation, orthostatic symptoms, cardiac symptoms
- Dose and duration - Higher doses and longer duration increase risk of adverse effects
Step 2: Discontinuation Strategy
- Trazodone: Taper gradually over 1-2 weeks to avoid withdrawal-induced insomnia 2. Do not stop abruptly.
- Hydroxyzine: Can typically stop immediately given short half-life, but monitor for rebound 5
Step 3: Transition to Evidence-Based Treatment
First-line therapy should be CBT-I (Cognitive Behavioral Therapy for Insomnia) 4, 7. This is the only intervention with Standard-level evidence for chronic insomnia 4.
If pharmacotherapy is necessary, the evidence-based sequence is 4:
First choice: Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon
- Use lowest effective dose
- Counsel on FDA warning about sleep behaviors (sleepwalking, sleep driving) 1
Second choice: Low-dose doxepin (3-6 mg) - the only antidepressant with positive evidence 1
Avoid entirely:
Step 4: Ongoing Management
- Combine pharmacotherapy with CBT-I when possible 4, 8, 4
- Follow every few weeks initially to assess effectiveness and side effects 4
- Use lowest effective dose and attempt to taper when conditions allow 4
- Consider intermittent dosing (3 nights per week) rather than nightly for long-term use 4
Critical Pitfalls to Avoid
Do not increase the dose when trazodone or hydroxyzine stop working - this indicates tolerance, not inadequate dosing 1
Do not combine with other sedating medications - both potentiate CNS depressants and increase risk of adverse effects 2, 5
Do not use in elderly patients without extreme caution - both carry high risk of falls, confusion, and paradoxical reactions in this population 8, 1, 5
Do not ignore cardiac risk factors - both can prolong QT interval and cause arrhythmias 2, 5
Do not prescribe long-term without CBT-I trial - pharmacotherapy alone has poor long-term outcomes 4, 7
Special Populations
Older adults: The 2009 geriatric guidelines note that risks of antihistamines and trazodone outweigh benefits in elderly patients 8. Start with CBT-I exclusively if possible.
Patients with depression: Even in depressed patients, trazodone at sleep doses (50-150 mg) does not adequately treat depression 4. Full-dose antidepressant therapy plus CBT-I is more appropriate than relying on trazodone for both conditions 4.
Patients with cardiac disease: Both medications carry cardiac risks and should be avoided 2, 5.